PUBLICATION
Global Business Reports
United States Biopharmaceuticals 2017
July 27, 2017
A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is framed by uncertainty in light of the country’s recent political transition. Nevertheless, the industry is robust and ready to adapt, already reacting to recent negative media attention relating to drug pricing and price increases. With an increasing amount of innovation stemming from small biotechnology companies and projects spun out from universities into start-ups, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange.
RELATED INTERVIEWS MORE INTERVIEWS
TrialScope helps trial sponsors to comply with disclosure regulations and internal transparency policies for jurisdictions across the world and is developing a program to provide easily intelligible interpretations of trial results for the patients that are involved in trials.
Almac Clinical Technologies designs and deploys complex software that helps trial sponsors automate complex decisions that occur in clinical trials.
UL helps companies meet safety and compliance standards and regulations across the pharma industry.
Chromocell is using its own Chrmovert technology to provide alternative pain blockers to opioids.
RELATED ARTICLES MORE ARTICLES
Quality: A Means for Value Creation
United States Biopharmaceuticals 2017
Firms must shift focus from Quality for Compliance to Quality as a Culture by keeping the end patient in mind.
Regulating Quality
United States Biopharmaceuticals 2017
Maintaining Safeguards Whilst Lowering Barriers to Market Entry.
RECENT PUBLICATIONS
Mexico Chemicals 2024
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
MORE PREVIOUSLY PUBLISHED
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
MORE PREVIOUSLY PUBLISHED
MACIG
"We plan to double our copper production by the end of the decade. There remains significant upside potential in the gold industry, and the copper operations are strategic and additive to that."
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
